May be taken with or without food. Swallow whole, do not chew/crush.
|
Hypersensitivity to aspirin, dipyridamole, or NSAIDs. Syndrome of asthma, rhinitis and nasal polyps; active gastric or duodenal ulcers, history of active peptic ulcer disease, experienced gastric pain with previous use of aspirin/dipyridamole; bleeding disorders, history of haemorrhagic CVA, haemorrhagic diathesis or coagulation disorders (e.g. hypoprothrombinaemia, haemophilia). Children and adolescents with viral infections. Severe renal (GFR <10 mL/min) and hepatic impairment. Pregnancy (3rd trimester). Concomitant use with methotrexate (>15 mg/week doses).
|
Patient with erosive gastritis, CV disease (e.g. hypotension, coronary artery disease, unstable angina, recent MI, left ventricular outflow obstruction, haemodynamic instability), myasthenia gravis, G6PD deficiency. Patient undergoing surgery; discontinue treatment 1-2 weeks prior to procedure. Interrupt treatment for 24-48 hours before pharmacological stress testing with IV dipyridamole or other adenosinergic agents. Not interchangeable with the individual preparations of aspirin and dipyridamole. Mild to moderate renal and hepatic impairment. Pregnancy (1st-2nd trimester) and lactation. Patient Counselling This drug may cause dizziness and confusion, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure, CBC, Fe studies, ferritin, stools for occult blood, LFTs and renal function tests with prolonged therapy. Assess for signs and symptoms of gastrointestinal ulcers and bleeding, including occult bleeding; stroke or TIA particularly in patients taking concurrent aspirin for cardiac indications.
|
Significant: Intracranial haemorrhage, headache or migraine-like headache, gastrointestinal effects (e.g. stomach pain, heartburn, nausea, vomiting, gastrointestinal bleeding), hepatic insufficiency (e.g. elevated hepatic enzymes, hepatic failure), salicylate sensitivity, tinnitus, hypersensitivity reactions (e.g. rash, severe urticaria, bronchospasm, angioedema); exacerbated pre-existing hypotension, precipitated chest pain; dipyridamole incorporated into gallstones.
Blood and lymphatic system disorders: Anaemia.
Cardiac disorders: Syncope, worsening of coronary artery disease symptoms.
Gastrointestinal disorders: Dyspepsia, diarrhoea.
Musculoskeletal and connective tissue disorders: Myalgia.
Nervous system disorders: Dizziness.
Psychiatric disorders: Confusional state.
Respiratory, thoracic and mediastinal disorders: Epistaxis.
Vascular disorders: Haemorrhage.
Potentially Fatal: Rarely, Reye's syndrome.
|
|
|
Increased risk of bleeding with anticoagulants (e.g. coumarins, heparin), antiplatelets (e.g. clopidogrel, ticlopidine), anagrelide, fibrinolytics, NSAIDs (chronic use), SSRIs.
Aspirin: Increased risk of gastrointestinal bleeding with corticosteroids. May diminish the hypotensive effects of ACE inhibitors and β-blockers. May result in high serum levels and toxicity of acetazolamide. Enhanced effects of phenytoin, valproic acid. May decrease the effects of diuretics. May antagonise the action of uricosuric agents (e.g. probenecid, sulfinpyrazone). May increase the effectiveness of oral hypoglycaemics.
Dipyridamole: Increased plasma levels and CV effects of adenosine. Increased CV effects of regadenoson. May antagonise the anticholinesterase effects of cholinesterase inhibitors causing potential aggravation of myasthenia gravis. May increase the hypotensive effects of blood pressure-lowering agents.
|
|
|
B01AC07 - dipyridamole ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
|
Sign Out
